S-Adenosylmethionine affects ERK1/2 and STAT3 pathway in androgen-independent prostate cancer cells

BACKGROUND: The most critical point in the treatment of prostate cancer is the progression towards a hormone-refractory tumour, making research on alternative therapies necessary. This study focused on the methyl donor S-adenosylmethionine (SAM), which is known to act as an antitumourigenic in sever...

Descripción completa

Detalles Bibliográficos
Autor principal: Schmidt, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262802/
https://www.ncbi.nlm.nih.gov/pubmed/35303200
http://dx.doi.org/10.1007/s11033-022-07331-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262802/
https://www.ncbi.nlm.nih.gov/pubmed/35303200
http://dx.doi.org/10.1007/s11033-022-07331-2

Ejemplares similares